Cullinan Therapeutics, Inc. (CGEM) financial statements and ratios from SEC XBRL: revenue $22.21M (TTM), net margin -989.9%, revenue growth -25.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $22.21M |
| Net Margin | -989.9% |
| Revenue Growth (YoY) | -25.1% |
| FCF Growth (YoY) | 21.0% |
| Price / Book | 4.28 |
| Price / Sales | 81.22 |
| FCF Yield | -10.0% |
| Altman Z-Score | 16.95 (safe) |
| Sector P/E (Healthcare) | 21.6 |
CGEM overview · CGEM earnings · CGEM KPIs · CGEM investor relations · CGEM ownership · CGEM peers · CGEM filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.